GeparOcto, NCT02125344 / 2014-000619-14: A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer |
|
|
| Completed | 3 | 961 | Europe | non-pegylated liposomal doxorubicin, Myocet, Carboplatin, Carbomedac, Paclitaxel, var., Epirubicin, Farmorubicin, Cyclophosphamide, Endoxan, Pertuzumab, Perjeta, Trastuzumab, Herceptin, Ferric carboxymaltose, Ferinject | German Breast Group, Amgen, Roche Pharma AG, Teva Pharmaceuticals USA, Vifor Pharma | Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer, HER2 Positive Breast Cancer, Inflammatory Breast Cancer | 11/16 | 01/17 | | |
